Fertilizante de liberação lenta no desenvolvimento de mudas de Eucalyptus grandis.

Uma das ações mais importantes para aumentar a produção de mudas de essências florestais é a fertilização do substrato. A utilização de fertilizante de liberação lenta (FLL) pode contribuir para a obtenção de mudas de melhor qualidade. O objetivo do trabalho foi avaliar doses crescentes de FLL e fertilizante convencional (FC), bem como comparar esses fertilizantes no desenvolvimento de mudas de Eucalyptus grandis. O estudo foi realizado na região do Vale do Itajaí, SC. Os tratamentos foram a adição de FLL e FC para cada experimento nas seguintes doses de formulado: T1 ? 0 kg (testemunha); T2 ? 2 kg; T3 ? 4 kg; T4 ? 6 kg; T5 ? 8 kg e T6 ? 10 kg.m-3 de substrato-base. Decorridos 174 dias da semeadura, foram analisadas as variáveis altura total, diâmetro do colo, biomassa fresca da parte aérea, biomassa seca da parte aérea, biomassa seca da raiz, biomassa seca total, dose de máxima eficiência técnica e teores de nutrientes da parte aérea das mudas de cada tratamento. Em todos os tratamentos houve resposta positiva no desenvolvimento das mudas, entretanto as mudas tiveram melhor crescimento sob doses entre 9,1 e 12,9 kg.m-3 de fertilizante de liberação lenta

o 002geographic variation in systemic treatment of metastatic pancreatic adenocarcinoma mpac patients in real world across europe

n/

p 167symptoms reported at initial diagnosis of metastatic pancreatic adenocarcinoma m pac in routine clinical practice and variation in frequencies across europe

n/

pd 004baseline characteristics and second line treatment for metastatic pancreatic adenocarcinoma mpac patients receiving first line folfirinox gemcitabine nab paclitaxel or gemcitabine monotherapy in routine clinical practice across europe

n/

Avaliação da produção de matéria seca radicular de diferentes coberturas de solo, no período de inverno nas entrelinhas de erva-mate no município de Aurea, RS.

bitstream/CNPF-2009-09/16600/1/com_tec27.pd

Produtividade de massas radicular e aérea de diferentes coberturas verdes em plantio de erva-mate sobre cambissolo textura argilosa, no Município de Ivaí-PR.

bitstream/CNPF-2009-09/32742/1/com_tec79.pd

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group

Next-generation sequencing (NGS) allows sequencing of a high number of nucleotides in a short time frame at an affordable cost. While this technology has been widely implemented, there are no recommendations from scientific societies about its use in oncology practice. The European Society for Medical Oncology (ESMO) is proposing three levels of recommendations for the use of NGS. Based on the current evidence, ESMO recommends routine use of NGS on tumour samples in advanced non-squamous non-small-cell lung cancer (NSCLC), prostate cancers, ovarian cancers and cholangiocarcinoma. In these tumours, large multigene panels could be used if they add acceptable extra cost compared with small panels. In colon cancers, NGS could be an alternative to PCR. In addition, based on the KN158 trial and considering that patients with endometrial and small-cell lung cancers should have broad access to anti-programmed cell death 1 (anti-PD1) antibodies, it is recommended to test tumour mutational burden (TMB) in cervical cancers, well- and moderately-differentiated neuroendocrine tumours, salivary cancers, thyroid cancers and vulvar cancers, as TMB-high predicted response to pembrolizumab in these cancers. Outside the indications of multigene panels, and considering that the use of large panels of genes could lead to few clinically meaningful responders, ESMO acknowledges that a patient and a doctor could decide together to order a large panel of genes, pending no extra cost for the public health care system and if the patient is informed about the low likelihood of benefit. ESMO recommends that the use of off-label drugs matched to genomics is done only if an access programme and a procedure of decision has been developed at the national or regional level. Finally, ESMO recommends that clinical research centres develop multigene sequencing as a tool to screen patients eligible for clinical trials and to accelerate drug development, and prospectively capture the data that could further inform how to optimise the use of this technology

Desenvolvimento de leguminosas arbóreas em sistema de alley cropping, em solos degradados pela mineração de xisto pirobetuminoso, em São Mateus do Sul, PR.

bitstream/CNPF-2009-09/16607/1/com_tec28.pd

Generalisation of the Picture Exchange Communication System (PECS) across transfer facilitated and non-facilitated settings.

The purpose of this study was to investigate the extent to which PECS would generalise from the training setting to other familiar settings as a function of properties of the settings. It was predicted that PECS would generalise better to the setting where PECS use facilitated was by having the same communicative partners and items available. Three preschool children all with a diagnosis of Autism Spectrum Disorder (ASD) were trained to use the Picture Exchange Communication System (PECS) to a minimum proficiency level of Phase 3. The experiment employed an ABA single case design with multiple target measures, replicated across participants, acknowledging that observations in the first baseline would be zero. Transfer of PECS across settings varied for each participant. One participant generalised PECS to the facilitated environment more than the non-facilitated environment as predicted. Another participant transferred PECS better to the non-facilitated environment compared to the facilitated environment contrary to the research prediction. The final participant did not generalise PECS to either environment, switching to functional verbal communication instead

High Expression of TROP2 Is Associated With Aggressive Localized Prostate Cancer and Is a Candidate Urinary Biomarker

Distinguishing indolent from clinically significant localized prostate cancer is a major clinical challenge and influences clinical decision-making between treatment and active surveillance. The development of novel predictive biomarkers will help with risk stratification, and clinical decision-making, leading to a decrease in over or under-treatment of patients with prostate cancer. Here, we report that Trop2 is a prognostic tissue biomarker for clinically significant prostate cancer by utilizing the Canary Prostate Cancer Tissue Microarray (CPCTA) cohort composed of over 1100 patients from a multi-institutional study. We demonstrate that elevated Trop2 expression is correlated with worse clinical features including Gleason score, age, and pre-operative PSA levels. More importantly, we demonstrate that elevated Trop2 expression at radical prostatectomy predicts worse overall survival in men undergoing radical prostatectomy. Additionally, we detect shed Trop2 in urine from men with clinically significant prostate cancer. Our study identifies Trop2 as a novel tissue prognostic biomarker and a candidate non-invasive marker for prostate cancer